

Listing of Claims

Please amend the claims as follows. This listing of claims replaces all prior versions and listings of claims in the application.

Claims 1 – 123 (Canceled)

124. (Currently Amended) A method of reducing inflammation in gene therapy in a subject, comprising ~~delivering to the subject a complement modulator, administering a composition comprising a viral vector comprising a complement modulator expressed on the surface of the vector,~~ wherein the complement modulator inhibits complement activation.

Claim 125. (Canceled)

126. (Withdrawn) The method of claim 124, wherein the complement inhibitor is SCR 13-15.

127. (Withdrawn) The method of claim 124, wherein the complement inhibitor is Crry.

Claims 128-162 (Canceled)

163. (Currently Amended) The method of ~~claim 124~~ claim 160, wherein the viral vector is an adenoviral vector.

164. (Currently Amended) The method of ~~claim 124~~ claim 163, wherein the viral vector is an AAV.

165. (Canceled)

166. (New) The method of claim 124, wherein the complement modulator comprises two

repeats of ED1 and a linker.

167. (New) The method of claim 166, wherein the complement modulator further comprises a His-tag.

168. (New) The method of claim 124, wherein the complement modulator comprises SEQ ID NO:9.

169. (New) The method of claim 124, wherein the complement modulator comprises the ed1 region of the Sh-TOR protein of Schistosoma parasite.

170. (New) The method of claim 124, wherein the viral vector further comprises a gene of interest.

171. (New) The method of claim 124, wherein the viral vector further comprises a targeting motif.

172. (New) The method of claim 171, wherein the targeting motif is selected from the group consisting of the tripeptide RGD sequence, fiber-fibritin chimeras, CD40L, E-selectin targeting peptides, and SSTR-avid peptide.

173. (New) The method of claim 124, wherein the viral vector further comprises a promoter.

174. (New) The method of claim 124, wherein the viral vector further comprises a reporter nucleic acid.

175. (New) The method of claim 124, wherein the viral vector further comprises a CAR binding site mutation or an ablation of integrin-binding.

.